Literature DB >> 9726378

Adenosine A1 and A2A receptor antagonists stimulate motor activity: evidence for an increased effectiveness in aged rats.

P Popoli1, R Reggio, A Pèzzola, K Fuxe, S Ferré.   

Abstract

The motor effects of selective adenosine A1 and A2A receptor antagonists were tested in young (2 months) and aged (24 months) Wistar rats. In young rats, both the selective A2A receptor antagonist 5-amino-7-(2-phenylethyl)-2-2(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazo++ + lo[1,5-c]pyrimidine (SCH 58261, minimal effective dose 2 mg/kg intraperitoneally (i.p.)) and the selective A1 receptor antagonist 8-cyclopentyl-1,3-dimethylxanthine (CPT, minimal effective dose 1.2 mg/kg i.p.) stimulated motor activity. In old rats, both compounds induced significant motor activation starting from doses lower than those required in young animals. Specifically, the minimal effective doses of SCH 58261 and CPT in aged rats were 1 and 0.6 mg/kg i.p, respectively. The results indicate that both adenosine A1 and A2A receptors play a functional role in the control of motor activity, and, therefore, the blockade of both receptor subtypes is involved in the motor stimulating properties of methylxanthines. Also the evidence indicates, for the first time, that in aged animals the motor inhibitory adenosinergic tone seems to be increased with respect to young animals.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9726378     DOI: 10.1016/s0304-3940(98)00533-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  10 in total

Review 1.  Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy.

Authors:  Detlev Boison; Philipp Singer; Hai-Ying Shen; Joram Feldon; Benjamin K Yee
Journal:  Neuropharmacology       Date:  2011-02-17       Impact factor: 5.250

2.  Stimulant effects of adenosine antagonists on operant behavior: differential actions of selective A2A and A1 antagonists.

Authors:  Patrick A Randall; Eric J Nunes; Simone L Janniere; Colin M Stopper; Andrew M Farrar; Thomas N Sager; Younis Baqi; Jörg Hockemeyer; Christa E Müller; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2011-02-24       Impact factor: 4.530

3.  Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice.

Authors:  M El Yacoubi; C Ledent; M Parmentier; R Bertorelli; E Ongini; J Costentin; J M Vaugeois
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

Review 4.  Modulators of nucleoside metabolism in the therapy of brain diseases.

Authors:  Detlev Boison
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

Review 5.  Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.

Authors:  Jacobus P Petzer; Neal Castagnoli; Michael A Schwarzschild; Jiang-Fan Chen; Cornelis J Van der Schyf
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

6.  Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade.

Authors:  Rodrigo A Cunha
Journal:  Purinergic Signal       Date:  2005-03-17       Impact factor: 3.765

7.  A2A Adenosine Receptor Antagonism Reverts the Blood-Brain Barrier Dysfunction Induced by Sleep Restriction.

Authors:  Gabriela Hurtado-Alvarado; Emilio Domínguez-Salazar; Javier Velázquez-Moctezuma; Beatriz Gómez-González
Journal:  PLoS One       Date:  2016-11-28       Impact factor: 3.240

8.  Impact of Melatonin Deficit on Emotional Status and Oxidative Stress-Induced Changes in Sphingomyelin and Cholesterol Level in Young Adult, Mature, and Aged Rats.

Authors:  Jana Tchekalarova; Zlatina Nenchovska; Lidia Kortenska; Veselina Uzunova; Irina Georgieva; Rumiana Tzoneva
Journal:  Int J Mol Sci       Date:  2022-03-04       Impact factor: 5.923

Review 9.  Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development.

Authors:  Chrisna Matthee; Gisella Terre'Blanche; Lesetja J Legoabe; Helena D Janse van Rensburg
Journal:  Mol Divers       Date:  2021-06-27       Impact factor: 3.364

10.  A Combination of Caffeine, TeaCrine® (Theacrine), and Dynamine® (Methylliberine) Increases Cognitive Performance and Reaction Time Without Interfering With Mood in Adult Male Egamers.

Authors:  Jaime L Tartar; Jonathan B Banks; Mykola Marang; Frankie Pizzo; Jose Antonio
Journal:  Cureus       Date:  2021-12-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.